Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18848276 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL18848250 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL18848361 | 0.93 | CTSK (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL18848281 | 0.93 | CTSK (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL18848226 | 0.93 | CTSK (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL1884858 | 0.81 | CTSK (0.38) | CTSKNAAAEPHX1 | |
| SCHEMBL13943478 | 0.79 | NAAA (0.39) | CTSKNAAAEPHX1 | |
| SCHEMBL3884167 | 0.79 | NAAA (0.36) | CTSKNAAA | |
| SCHEMBL18848343 | 0.78 | CA12 (0.35) | — | |
| SCHEMBL18848243 | 0.78 | CA12 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | SLC10A1, ABCB11, SLC10A2 | CHRNB2 4731/4885CHRNB4 4644/4885CHRNA3 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.